Resona Asset Management Co. Ltd. purchased a new stake in shares of Danaher Co. (NYSE:DHR – Free Report) in the 4th quarter, HoldingsChannel reports. The firm purchased 392,156 shares of the conglomerate’s stock, valued at approximately $90,145,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank bought a new stake in shares of Danaher in the fourth quarter worth about $2,130,740,000. Raymond James Financial Inc. purchased a new stake in Danaher in the 4th quarter worth approximately $391,172,000. Van ECK Associates Corp grew its position in shares of Danaher by 6,862.7% in the 4th quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock worth $213,452,000 after buying an additional 916,513 shares during the last quarter. Parnassus Investments LLC increased its stake in shares of Danaher by 31.8% during the fourth quarter. Parnassus Investments LLC now owns 3,105,388 shares of the conglomerate’s stock valued at $712,842,000 after buying an additional 749,136 shares during the period. Finally, Proficio Capital Partners LLC raised its holdings in shares of Danaher by 29,287.7% during the fourth quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock valued at $135,189,000 after acquiring an additional 586,925 shares in the last quarter. 79.05% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on DHR
Danaher Price Performance
Shares of Danaher stock opened at $181.42 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52 week low of $181.20 and a 52 week high of $281.70. The stock’s 50-day simple moving average is $209.99 and its 200-day simple moving average is $234.26. The company has a market capitalization of $129.66 billion, a price-to-earnings ratio of 34.36, a PEG ratio of 2.66 and a beta of 0.86.
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the firm posted $2.09 EPS. As a group, analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.32 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Friday, March 28th. Danaher’s payout ratio is currently 24.24%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- NYSE Stocks Give Investors a Variety of Quality Options
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- Canada Bond Market Holiday: How to Invest and Trade
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.